CPSC Warns Parents to Discard Hongmingzheng Crib Bumpers Over Suffocation Risk
The U.S. Consumer Product Safety Commission issued a warning on June 4, 2026, urging parents to immediately stop using and discard Hongmingzheng crib bumpers (model JP0128) sold on Amazon, which violate a federal ban on padded crib bumpers. Padded crib bumpers have been banned under the Safe Sleep for Babies Act due to suffocation and airway obstruction risks to infants. The warning highlights ongoing safety concerns with baby products sold online and underscores the importance of following product recalls and safety guidance.
The CPSC issued a formal warning against Hongmingzheng crib bumpers, specifically model JP0128 identifiable by printed labels and six tie strings, which were sold on Amazon during April and May 2026. The products violate the Safe Sleep for Babies Act, which bans padded crib bumpers due to their potential to block infant airways and cause serious injury or death. The seller, Chinese company Kunminghongyuanxiangshanmaoyouxiangongsi operating as Hongmingzheng, received a Notice of Violation from the CPSC. Product liability attorney Timothy S. Trecek emphasized that the case reflects a broader problem with online baby product sales and noted that research has consistently demonstrated padded bumpers pose significant suffocation and entrapment risks. The CPSC reiterated safe sleep guidance, recommending that infants sleep on firm, flat surfaces on their backs with only a fitted sheet, and that parents should remove rather than add items to cribs.
What's missing
The article does not specify whether any injuries or deaths have been documented from these particular Hongmingzheng bumpers, or provide information about how many units were sold or how many consumers may be affected.
What different sources said
- NewsweekCenter
Parents Warned to Stop Using Hongmingzheng Crib Bumpers Due to Fatal Risk
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.